SuperworthEloxx Pharmaceuticals revenue ELOX
Sales by quarter and over the last twelve months, from 2011.
- Last 12 months, to Dec 31, 2012
- n/m
- a quarter missing
- Latest quarter, Q2 FY13
- $0
- −100% on a year earlier
- Fiscal year 2012
- n/a
Eloxx Pharmaceuticals' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY13, it was $0, down 100% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2012 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier |
|---|---|---|---|
| Q2 FY13 | $0 | −100% | |
| Q4 FY12 | $0 | n/a | |
| Q3 FY12 | $0 | n/a | |
| Q2 FY12 | $200K | n/a |
Against its peers
Companies in Healthcare nearest Eloxx Pharmaceuticals' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| ELOXEloxx Pharmaceuticals | n/m | |
| ATNMActinium Pharmaceuticals | n/m | |
| APTAlpha Pro Tech | $61.9M | +6% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| NEPHNephros | $20.7M | +24% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| ICCCImmucell | $30.7M | +8% a year |
| KEQUKewaunee Scientific | $277.2M | +5% a year |
| PDEXPro DEX | $77.5M | +16% a year |
| PLXProtalix BioTherapeutics | $80.6M | +30% a year |
| NATRNatures Sunshine Products | $492M | +7% a year |
| Peer median | $77.5M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Eloxx Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.